EASL Congress

EASL Congress
May 27-30, 2026
Barcelona, Spain

The European Association for the Study of the Liver®.

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (16)

    Safety of bulevirtide 10 mg is consistent across demographic and clinical subgroups: results from an integrated analysis

    • Author(s): Aleman, S
    • bulevirtide
    • Liver Diseases

    Factors associated with lack of alanine aminotransferase normalisation in patients with chronic hepatitis B virus after 8 years of tenofovir-based treatment

    • Author(s): Lai-Hung Wong, G
    • vemlidy
    • Liver Diseases

    Safety and efficacy of long-term tenofovir alafenamide treatment in patients aged 60 years and older with chronic hepatitis B: experience from two phase 3 clinical trials

    • Author(s): Fung, S
    • vemlidy
    • Liver Diseases

    Efficacy and safety of seladelpar in patients with primary biliary cholangitis and alkaline phosphatase levels 1-1.67 × upper limit of normal: interim results from the open-label ASSURE study up to 24 months

    • Author(s): Levy, C
    • livdelzi
    • Liver Diseases

    Efficacy and safety of seladelpar in patients with primary biliary cholangitis and cirrhosis, including those with clinical signs of portal hypertension, in the open-label ASSURE study with up to 4 years of treatment

    • Author(s): Gulamhusein, A
    • livdelzi
    • Liver Diseases

    Efficacy and safety of seladelpar vs placebo in patients with primary biliary cholangitis and metabolic syndrome in the pivotal phase 3 RESPONSE study

    • Author(s): Mayo, M
    • livdelzi
    • Liver Diseases

    Transcriptomic profiling reveals distinct immune signatures in chronic hepatitis B and identifies blood transcriptional modules as sociated with hepatitis B e antigen loss following therapeutic vaccination with GS-2829 and GS-6779

    • Author(s): Cortese, M
    • gs-6779
    • gs-2829
    • Liver Diseases

    Impact of bulevirtide treatment on patient-reported outcomes among patients with hepatitis delta in Europe

    • Author(s): Buti, M
    • bulevirtide
    • Liver Diseases

    NTCP polymorphisms do not impact Bulevirtide antiviral activity or HDV treatment response

    • Author(s): Manhas, S
    • bulevirtide
    • Liver Diseases

    Integrated efficacy analysis of bulevirtide 10 mg from studies MYR204 and MYR301 at weeks 48 and 96 across subgroups

    • Author(s): Streinu-Cercel, A
    • bulevirtide
    • Liver Diseases

    Bulevirtide monotherapy is safe and well tolerated in chronic hepatitis delta: an integrated safety analysis of bulevirtide clincal trials at week 96

    • Author(s): Asselah, T
    • bulevirtide
    • Liver Diseases

    Seladelpar effect on lipids and muscle safety with concomitant statin use in patients with primary biliary cholangitis: interim results from the open-label ASSURE study with up to 4 years of treatment

    • Author(s): Bowlus, C
    • livdelzi
    • Liver Diseases

    Efficacy and safety of seladelpar in patients with primary biliary cholangitis and risk factors for progression including younger age at diagnosis or higher liver stiffness in the pivotal response study

    • Author(s): Mayo, M
    • livdelzi
    • Liver Diseases

    Baseline and on-treatment characteristics of HBeAg-positive patients and correlates of HBeAg loss following GS-2829 and GS- 6779 therapeutic vaccination in virally suppressed patients with chronic hepatitis B

    • Author(s): Wen-Juei Jeng, R
    • gs-6779
    • gs-2829
    • Liver Diseases

    Seladelpar leads to decrease in serum proteins associated with PBC disease severity: proteomic analysis from pivotal RESPONSE trial

    • Author(s): Trauner, M
    • livdelzi
    • Liver Diseases

    Biochemical response is associated with liver stiffness stability in patients with primary biliary cholangitis treated with seladelpar for up to 3 years in the ongoing open-label ASSURE study

    • Author(s): Hirschfield, G
    • livdelzi
    • Liver Diseases